P2s: Practice-changing, Paradigm-shifting Clinical Trials in Urology - AUA Annual Meeting

advertisement

Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.

  1. Home
  2. Abstracts
  3. P2s Clinical Trials in Urology

P2s: Practice-changing, Paradigm-shifting Clinical Trials in Urology

AUA2026 – Abstracts

About the Program

Practice-changing, Paradigm-shifting Clinical Trials in Urology (P2s) are designed to showcase exceptional, groundbreaking studies that are expected to change the day-to-day practice of urology. Reserved for the most impactful studies, P2s will be presented on the Plenary stage, providing the greatest exposure and profile for the research. Results should not have been presented previously at any other meeting.

Important Dates

Submission Site Opens

January 7

Submission Site Closes

February 16, 11:59 p.m. ET

Eligible Studies

The AUA is looking for studies that address scientific questions of particular interest to urologists. Studies should include primary data using:

  1. A randomized clinical trial design (phase II or III trials)
    OR
  2. Prospective, observational cohort studies that compare therapies and/or highlight novel and high-impact interventions that will change clinical practice

Retrospective studies, basic science studies, meta-analyses, survey research, and/or case series and reports are NOT appropriate for submission. "Encore" presentations are not eligible for presentation and, while secondary analyses of previously presented trials are eligible for submission, these analyses must truly be new findings and be of substantial significance to be accepted for presentation.

The meeting organizers understand that the final results for important phase 3 clinical trials are often not available at the deadline for abstract submission. To this end, "shell" abstracts with data placeholders will be considered but authors should discuss with the AUA Secretary prior to submission. If you intend to submit a shell abstract, please contact us before the deadline at speakers@AUAnet.org.

Submission Requirements

P2s must contain the following elements.

  • Title (limited to 255 characters, including spaces)
  • Body (limited to 2,280 characters, not including spaces). Studies should present prospective, original research that highlights novel and high-impact research with practice-changing implications. The body must be informative and detailed. The following sections are required:
    • Introduction and objectives
    • Methods
    • Results
    • Conclusions
      • The AUA recognizes that, particularly in the case of large Phase 3 studies, analysis may not be completed by the submission deadline. If this is the case, please make note in the conclusions section. During submission, you will be required to enter the background and methods sections, and provide the primary clinical endpoint for analysis, type of analysis, date of planned analysis, and planned statistical methods.
      • Those selected for presentation will be required to provide the final data set and analysis two weeks before the Annual Meeting.
    • Source of funding
      • Authors must fully disclose all funding sources. If there is no support, please write "None".
    • Optional: A maximum of two figures or graphics may be included. Each figure or graphic counts as 225 characters.
  • Author information
    • One author must be designated as the presenting author. 
    • The presenting author must disclose all financial relationships with ACCME-defined ineligible companies existing within the past 24 months.
    • The presenting author is not permitted to have financial relationships with ineligible companies (formerly commercial interests) that the ACCME would deem to be that of an owner or employee. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The AUA COI Review Work Group will determine which relationships are relevant and require mitigation.
      • Owners are defined as individuals who have an ownership interest in a company, except for stockholders of publicly traded companies, or holders of shares through a pension or mutual fund.
      • Employees are defined as individuals hired to work for another person or business (the employer) for compensation and who are subject to the employer's direction as to the details of how to perform the job.

The Program Committee has the authority to reject submissions that are incomplete, deemed purely for marketing purposes, duplicate submissions by the same authors and based on the same study population or data, not written in English, or in violation of the policies outlined herewithin.

Decision notifications will be sent to the presenting author. The presenting author is responsible for notifying any co-authors of the decision.

Policies

Any violation of these policies may subject the submission to rejection or removal from the AUA Annual Meeting.

Communications

During submission, AUA staff are authorized to communicate only with the presenting or corresponding author. Notifications regarding the outcome of a submission will be sent to the presenting author. After acceptance, AUA staff will communicate only with the presenting author regarding any matters, including withdrawal requests, which must be submitted in writing to speakers@AUAnet.org. Any queries or requests from co-authors or non-authors, including pharmaceutical companies or medical communications companies, must go through the presenting author. Any attempts to contact AUA directly by such individuals will not be responded to.

To ensure that you receive email notifications from AUA regarding your submission, please add AUA@mirasmart.com and speakers@AUAnet.org to your safe senders list.

Revisions

  • Prior to the submission deadline, the submitting author may log in to view, edit or delete their submission.
  • After the submission deadline, revisions to the content, including authorship, will not be accepted. It is the responsibility of the authors to ensure the submission is complete and free of spelling, grammatical and scientific errors.

Restrictions on the Use of Artificial Intelligence

  • Authors must refrain from using, sharing or uploading content accessed through AUA websites or educational activities into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
  • Authors must refrain from using, or sharing any AUA content/data to train, alter, inform, or otherwise affect any form of artificial intelligence; deep learning; machine learning; similar automated, autonomous, self-improving, or otherwise adaptive software model or program (whether automated as a whole or in part).

P2s Accepted for Presentation

Registration Requirement

  • The presenter must attend the 2026 AUA Annual Meeting in Washington, DC. The presenting author is required to respond to the invitation to present by the date indicated in the acceptance letter. Failure to register by this date will forfeit the opportunity to present and the article will be withdrawn from publication in The Journal of Urology®.
  • The presenter is responsible for any expenses associated with the preparation, submission and presentation of the abstract. Registration fee waivers and travel grants are not available for presenters.

Presentation

  • P2s accepted for presentation will be scheduled as part of the Plenary program.
  • At the time of acceptance notification, details will be communicated regarding the date and time of presentation along with guidance and expectations.

Publication

  • P2s accepted for the Annual Meeting are copyrighted by the American Urological Association and published in a supplement of The Journal of Urology® on the first day of the Annual Meeting. No part of materials published in The Journal of Urology® may be reproduced without written permission of the publisher. For information on requesting permission to reuse The Journal of Urology®, visit shop.lww.com/journal-permission or email publications@AUAnet.org.

Embargo

Please follow this link to view the embargo policy.

Contact

  • Questions related to the submission process can be sent to the Annual Meeting programs team at speakers@AUAnet.org.
  • Technical questions and issues with the submission site can be sent to AUA@mirasmart.com. You may also call the Mira Tech Support line at (866) 341-9590 between the hours of 8 a.m. and 5 p.m., Central Time (14:00 to 23:00 GMT), Monday through Friday.